Fibroblast Heterogeneity in Inflammatory Bowel Disease
International Journal of Molecular Sciences · 03.12.2024 · 25 (23) · 13008
DOI: 10.3390/ijms252313008 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 03.12.2024. Verfasst von Bo-Jun Ke und 2 weiteren Autor:innen. Beteiligte Einrichtung: Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases and Metabolism, KU Leuven, 3000 Leuven, Belgium. Hauptthemen laut MEDLINE: Fibroblasts, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taiwan (Ministry of Education)-KU Leuven Scholarship Programme, European Crohn’s and Colitis Organisation (ECCO) Grant 2020, European Crohn’s and Colitis Organisation (ECCO) Pioneer award 2023.
Abstract (Originalsprache)
Intestinal fibroblasts are pivotal players in maintaining tissue homeostasis and orchestrating responses to injury and inflammation within the gastrointestinal (GI) tract. Fibroblasts contribute significantly to the pathogenesis of inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis (UC), by secreting pro-inflammatory cytokines, modulating immune cell activity, and promoting fibrosis. In addition, fibroblasts play crucial roles in tissue repair and regeneration following acute injury or chronic inflammation. The dysregulation of fibroblast functions can lead to fibrotic complications, such as intestinal strictures and obstruction, which are common in advanced stages of IBD. Understanding the complex interplay between fibroblasts and other cell types in the intestine is essential to elucidate the underlying mechanisms of intestinal diseases and identify novel therapeutic targets. Future research aimed at deciphering the heterogeneity of intestinal fibroblasts and their dynamic roles in disease progression holds promise for the development of precision therapies to mitigate fibrosis and inflammation in intestinal disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases and Metabolism, KU Leuven, 3000 Leuven, Belgium.
- Gastroenterology Research Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50134 Florence, Italy.
ORCID-Profile: Gabriele Dragoni
Förderung
- Taiwan (Ministry of Education)-KU Leuven Scholarship Programme
- European Crohn’s and Colitis Organisation (ECCO) Grant 2020
- European Crohn’s and Colitis Organisation (ECCO) Pioneer award 2023
- European Union’s Horizon Europe Research & Innovation programme
- FWO
- KU Leuven Internal Funds
Zitieren
APA
Ke, B. J., Dragoni, G., & Matteoli, G. (2024). Fibroblast Heterogeneity in Inflammatory Bowel Disease. International Journal of Molecular Sciences, 25(23), 13008. https://doi.org/10.3390/ijms252313008
Vancouver
Ke BJ, Dragoni G, Matteoli G. Fibroblast Heterogeneity in Inflammatory Bowel Disease. International Journal of Molecular Sciences. 2024;25(23):13008. doi:10.3390/ijms252313008
BibTeX
@article{Ke2024,
author = {Ke, Bo-Jun and Dragoni, Gabriele and Matteoli, Gianluca},
title = {Fibroblast Heterogeneity in Inflammatory Bowel Disease},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {23},
pages = {13008},
doi = {10.3390/ijms252313008}
}
EUVIMED